MissionIR's  Instablog

Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
My blog:
MissionIR Blog
  • Global Phase 2b Clinical Data For CytRx, Inc. (CYTR) Aldoxorubicin Being Presented At The 18th Annual Connective Tissue Oncology Society Annual Meeting 0 comments
    Oct 23, 2013 2:29 PM | about stocks: CYTR

    CytRx Corp., a pharmaceutical research and development company that specializes in oncology, said in a release today that additional preliminary data from its Phase 2b clinical trial demonstrating aldoxorubicin's potential advantage over doxorubicin in its efficacy of treatment of soft tissue sarcoma will be presented at the 18th Annual Connective Tissue Oncology Society (CTOS) Meeting. The presentation will be taking place next Thursday, October 31 at 4:30 p.m. Eastern time at the Sheraton New York Times Square Hotel.

    Previous reports from the company said patients in the trial treated with aldoxorubicin had an Overall Response Rate (ORR) of 22%, while in contrast those administered the widely used chemotherapeutic agent doxorubicin had an ORR of 0%.

    "Because CTOS draws thought leaders in the treatment of sarcoma from around the world, it provides an ideal forum to gain awareness of this compelling data and to acquaint the oncologists with our phase 3 study in patients with relapsed or refractory soft tissue sarcomas," said CytRx President and CEO Steven A. Kriegsman. "Discoveries of new sarcoma treatments have been relatively few, particularly when compared with treatments for breast or prostate cancer, but the preliminary clinical results thus far drive our optimism that aldoxorubicin can fill an important medical need in patients with advanced soft tissue sarcoma."

    Soft tissue sarcoma is a cancer that occurs in muscle, fat, blood vessels, tendons, fibrous tissues, and connective tissue. It can arise anywhere in the body at any age. There are more than 30 types of this cancer, and more than 10,500 new cases are diagnosed each year in the U.S., according to statistics from the American Cancer Society.

    In addition to the Phase 2b trial for soft tissue sarcoma treatment efficacy, CytRx has received permission from the U.S. Food and Drug Administration for conducting a Phase 2 clinical trial with aldoxorubicin in glioblastoma, a difficult-to-treat and deadly brain cancer. The company plans to conduct a Phase 2 clinical trial in HIV-related Kaposi's sarcoma as well.

    For more information, please visit cytrx.com

    MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com

    Stocks: CYTR
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.